Clinical Trials
49 trialsNCT05420220 2026-05-28
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Completed
NCT04355156 2026-04-16
AXMUS-C
Imperial College London
Phase 2 Completed
NCT01409200 2026-03-03
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04258956 2025-09-11
AXAGIST
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Completed
NCT02597322 2025-04-06
AXIPAN
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT04562441 2025-01-10
NPC - AXEL Study : Axitinib-Avelumab
Chinese University of Hong Kong
Phase 2 Completed
NCT01693822 2024-11-21
A-PREDICT
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT02639182 2024-11-18
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Inc
Phase 2 Completed
NCT03990571 2024-10-18
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01263769 2024-09-19
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02636725 2024-07-12
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
University of Miami
Phase 2 Completed
NCT02579811 2023-06-29
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01385059 2023-03-07
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02489695 2022-09-06
AXIPAP
Centre Leon Berard
Phase 2 Completed
NCT02129647 2021-12-01
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NYU Langone Health
Phase 2 Completed
NCT02261207 2021-09-28
Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT03494816 2021-06-30
NAXIVA
Scottish Clinical Trials Research Unit
Phase 2 Completed
NCT02762513 2021-05-05
Expansion Trial for Axitinib In Head And Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01140737 2021-03-18
Axi-STS
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 2 Completed
NCT01321437 2021-01-20
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
University of California, Irvine
Phase 2 Completed
NCT01967576 2021-01-06
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01798446 2020-12-08
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
Seoul National University Hospital
Phase 2 Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT01334112 2019-12-12
AXITINIB
University Health Network, Toronto
Phase 2 Completed
NCT02700568 2019-10-22
FavorAx
Kidney Cancer Research Bureau
Phase 2 Completed
NCT01490866 2019-09-24
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02857712 2019-08-30
SGC-AX14
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT00569946 2019-06-05
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
Pfizer
Phase 2 Completed
NCT00219557 2019-05-14
AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Pfizer
Phase 2 Completed
NCT01562197 2019-01-24
AxiGII
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT03291314 2019-01-23
GliAvAx
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT01210495 2019-01-09
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
Pfizer
Phase 2 Completed
NCT01435122 2018-10-02
A Study of Axitinib in Advanced Carcinoid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01352728 2018-06-20
Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib
Chinese University of Hong Kong
Phase 2 Completed
NCT01174238 2018-06-08
A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma
University of California, San Francisco
Phase 2 Completed
NCT01558661 2017-11-28
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00835978 2017-05-30
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Pfizer
Phase 2 Completed
NCT01273662 2017-02-09
Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
National Taiwan University Hospital
Phase 2 Completed
NCT01469546 2016-08-29
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00389441 2013-11-25
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
Pfizer
Phase 2 Completed
NCT00600821 2013-11-08
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
Pfizer
Phase 2 Completed
NCT01255137 2013-06-27
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00615056 2013-04-19
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Pfizer
Phase 2 Completed
NCT00735904 2013-01-03
Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT00282048 2012-07-31
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
Pfizer
Phase 2 Completed
NCT00094055 2012-06-26
Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
Pfizer
Phase 2 Completed
NCT00094094 2012-06-26
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT00094107 2012-06-26
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Pfizer
Phase 2 Completed
NCT00071006 2012-06-08
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
Pfizer
Phase 2 Completed